{"filing":{"accession_number":"0001193125-26-354092","cik":"0001842295","ticker":"MAZE","company_name":"Maze Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-13","primary_document":"d135740d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526354092/d135740d8k.htm"},"events":[{"id":28276,"run_id":25853,"accession_number":"0001193125-26-354092","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Maze Therapeutics appointed two new directors to its Board: Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective August 13, 2026. Both appointees bring substantial clinical and biopharmaceutical leadership experience, including prior roles at major pharmaceutical companies and academic institutions.","company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":30163,"accession_number":"0001193125-26-354092","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new directors to Maze Therapeutics' Board: Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective August 13, 2026. The principal disclosed action is the appointment of these individuals to board positions, with detailed information about their qualifications, committee assignments, and compensation arrangements (pro rata cash retainer and option grants of 36,000 shares each). This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:20:35.283741+00:00","company_name":"","ticker":null,"filing_date":""},{"id":30164,"accession_number":"0001193125-26-354092","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Paula Johnson and Dr. Sophie Kornowski to Maze Therapeutics' Board of Directors, announced via press release on August 13, 2026. Both appointees bring substantial clinical and biopharmaceutical leadership experience (30+ and 35+ years respectively), including prior roles at major pharmaceutical companies and academic institutions. Board appointments of individuals with this caliber of experience are material governance events affecting the registrant's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:20:35.283741+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30163,"accession_number":"0001193125-26-354092","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new directors to Maze Therapeutics' Board: Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective August 13, 2026. The principal disclosed action is the appointment of these individuals to board positions, with detailed information about their qualifications, committee assignments, and compensation arrangements (pro rata cash retainer and option grants of 36,000 shares each). This is a material governance event affecting board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:20:35.283741+00:00","company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","filing_date":"2026-08-17"},{"id":30164,"accession_number":"0001193125-26-354092","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Dr. Paula Johnson and Dr. Sophie Kornowski to Maze Therapeutics' Board of Directors, announced via press release on August 13, 2026. Both appointees bring substantial clinical and biopharmaceutical leadership experience (30+ and 35+ years respectively), including prior roles at major pharmaceutical companies and academic institutions. Board appointments of individuals with this caliber of experience are material governance events affecting the registrant's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:20:35.283741+00:00","company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","filing_date":"2026-08-17"}]}